title: Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.
abstract: In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy for metastatic colorectal cancer. The drug was given by intravenous infusion at a dose of 700 mg/m2 every 21 days. There were no objective responses. Grades III and IV toxic effects were limited to granulocytopenia in 42% of courses and anemia in 5% of courses. There was one case of grade III increase in transaminases. Our results show that at this dose and schedule, CI-958 lacks activity against colorectal cancer.
authors.affiliation: Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Hoff
authors.forename: J A
authors.initials: JA
authors.lastname: Ellerton
authors.forename: S R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: R J
authors.initials: RJ
authors.lastname: Winn
authors.forename: J L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: R
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; C054558:ledoxantrone